Inbunden, Engelska, 2015
TRP Channels as Therapeutic Targets
From Basic Science to Clinical Use
1778 kr
Beställningsvara. Skickas inom 11-20 vardagar. Fri frakt över 249 kr.
Beskrivning
TRP Channels as Therapeutic Targets: From Basic Science to Clinical Use is authored by experts across academia and industry, providing readers with a complete picture of the therapeutic potential and challenges associated with using TRP channels as drug targets.
This book offers a unique clinical approach by covering compounds that target TRP channels in pre-clinical and clinical phases, also offering a discussion of TRP channels as biomarkers.
An entire section is devoted to the novel and innovative uses of these channels across a variety of diseases, offering strategies that can be used to overcome the adverse effects of first generation TRPV1 antagonists.
Intended for all researchers and clinicians working toward the development of successful drugs targeting TRP channels, this book is an essential resource chocked full of the latest clinical data and findings.
- Contains comprehensive coverage of TRP channels as therapeutic targets, from emerging clinical indications to completed clinical trials
- Discusses TRP channels as validated targets, ranging from obesity and diabetes through cancer and respiratory disorders, kidney diseases, hypertension, neurodegenerative disorders, and more
- Provides critical analysis of the complications and side effects that have surfaced during clinical trials, offering evidence-based suggestions for overcoming them
Produktinformation
- Utgivningsdatum: 2015-03-14
- Mått: 191 x 235 x undefined mm
- Vikt: 1 270 g
- Format: Inbunden
- Språk: Engelska
- Antal sidor: 536
- Förlag: Elsevier Science
- ISBN: 9780124200241
Utforska kategorier
Mer om författaren
Arpad Szallasi is a leading expert on the roles of TRP channels in health and disease. He was the first to provide a biochemical proof for the existence of the vanilloid (capsaicin) receptor, now known as TRPV1. Currently, he holds a Professor position at the 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.His research focuses on targeting of TRP channels for therapeutic purposes, with special emphasis on pain and inflammation.Arpad Szallasi obtained his MD degree Summa cum Laude from the Medical University School of Debrecen, Hungary (1984). He received his PhD degree in Pharmacology from the Karolinska Institute, Stockholm, Sweden (1995).Arpad Szallasi held several research positions both in academia (Karolinska Institute, Washington University, St. Louis, MO) and industry (Menarini Ricerche Sud, Pomezia, Italy) before pursuing a carrier in diagnostic pathology. Arpad Szallasi is a past President for the New Jersey Association of Blood Bank Professional and a former medical advisor to the American Red Cross.
Recensioner i media
"...provides a useful meta-review of a field in which numerous journal reviews have been published, few of which approach the big picture and detailed historical assessment of drug development and testing found here. Score: 84 - 3 Stars" --Doody's
Betyg & recensioner
0 recensioner
Inga recensioner tillgängliga.